Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 2, Issue 23

December 11 2018

In this Issue

EXCEPTIONAL CASE REPORTS
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY AND IMMUNOTHERAPY
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
PLATELETS AND THROMBOPOIESIS
TRANSFUSION MEDICINE
ERRATUM

EXCEPTIONAL CASE REPORTS

Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion
Clinical Trials & Observations

Andrew Jay Portuguese,Brea Lipe

View Articletitled, Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion

Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma
Clinical Trials & Observations

Chia-Ching Wang,Cassandra Thanh,Erica A. Gibson,Maya Ball-Burack,Louise E. Hogan,Benjamin Descours,Norman Jones,Alexander B. Carvidi,Sadie Munter,Sonia Bakkour,Michael P. Busch,Jeffrey M. Milush,Steven G. Deeks,Timothy J. Henrich

View Articletitled, Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma

Supplemental data

HEMATOPOIESIS AND STEM CELLS

GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cells

Moonjung Jung,Stefan Cordes,Jizhong Zou,Shiqin J. Yu,Xavi Guitart,So Gun Hong,Vinh Dang,Elaine Kang,Flavia S. Donaires,Sergio A. Hassan,Maher Albitar,Amy P. Hsu,Steven M. Holland,Dennis D. Hickstein,Danielle Townsley,Cynthia E. Dunbar,Thomas Winkler

View Articletitled, GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cells

Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling

David T. Mulder,Etienne R. Mahé,Mark Dowar,Youstina Hanna,Tiantian Li,Linh T. Nguyen,Marcus O. Butler,Naoto Hirano,Jan Delabie,Pamela S. Ohashi,Trevor J. Pugh

View Articletitled, CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling

Supplemental data

LYMPHOID NEOPLASIA

Ablation of miR-146b in mice causes hematopoietic malignancy

Takahiro Mitsumura,Yoshiaki Ito,Tomoki Chiba,Takahide Matsushima,Ryota Kurimoto,Yoko Tanaka,Tomomi Kato,Keisuke Uchida,Takashi Ito,Kouhei Yamamoto,Yoshinobu Eishi,Masanobu Kitagawa,Yasunari Miyazaki,Naohiko Inase,Hiroshi Asahara

View Articletitled, Ablation of miR-146b in mice causes hematopoietic malignancy

Supplemental data

p53 regulates CD46 expression and measles virus infection in myeloma cells

Anne Lok,Geraldine Descamps,Benoit Tessoulin,David Chiron,Marion Eveillard,Catherine Godon,Yannick Le Bris,Astrid Vabret,Celine Bellanger,Laurent Maillet,Sophie Barillé-Nion,Marc Gregoire,Jean-François Fonteneau,Steven Le Gouill,Philippe Moreau,Frederic Tangy,Martine Amiot,Agnes Moreau-Aubry,Catherine Pellat-Deceunynck

View Articletitled, p53 regulates CD46 expression and measles virus infection in myeloma cells

Supplemental data

The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma

Kyle Runckel,Matthew J. Barth,Cory Mavis,Juan J. Gu,Francisco J. Hernandez-Ilizaliturri

View Articletitled, The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma

Supplemental data

MYELOID NEOPLASIA

The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy

Suhu Liu,Anna E. Marneth,Gabriela Alexe,Sarah R. Walker,Helen I. Gandler,Darwin Q. Ye,Katherine Labella,Radhika Mathur,Patricia A. Toniolo,Michelle Tillgren,Prafulla C. Gokhale,David Barbie,Ann Mullally,Kimberly Stegmaier,David A. Frank

View Articletitled, The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy

Supplemental data

Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis

Catharina Wenk,Anne-Kathrin Garz,Sonja Grath,Christina Huberle,Denis Witham,Marie Weickert,Roberto Malinverni,Julia Niggemeyer,Michèle Kyncl,Judith Hecker,Charlotta Pagel,Christopher B. Mulholland,Catharina Müller-Thomas,Heinrich Leonhardt,Florian Bassermann,Robert A. J. Oostendorp,Klaus H. Metzeler,Marcus Buschbeck,Katharina S. Götze

View Articletitled, Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis

Supplemental data

PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation
Clinical Trials & Observations

Wenbin Xiao,Maheetha Bharadwaj,Max Levine,Noushin Farnoud,Friederike Pastore,Bartlomiej M. Getta,Anne Hultquist,Christopher Famulare,Juan S. Medina,Minal A. Patel,Qi Gao,Natasha Lewis,Janine Pichardo,Jeeyeon Baik,Brian Shaffer,Sergio Giralt,Raajit Rampal,Sean Devlin,Robert Cimera,Yanming Zhang,Maria E. Arcila,Elli Papaemmanuil,Ross L. Levine,Mikhail Roshal

View Articletitled, PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation

Supplemental data

PLATELETS AND THROMBOPOIESIS

Nfe2 is dispensable for early but required for adult thrombocyte formation and function in zebrafish

Megan S. Rost,Ilya Shestopalov,Yang Liu,Andy H. Vo,Catherine E. Richter,Sylvia M. Emly,Francesca G. Barrett,David L. Stachura,Michael Holinstat,Leonard I. Zon,Jordan A. Shavit

View Articletitled, Nfe2 is dispensable for early but required for adult thrombocyte formation and function in zebrafish

Supplemental data

Dynamins 2 and 3 control the migration of human megakaryocytes by regulating CXCR4 surface expression and ITGB1 activity

Praveen K. Suraneni,Seth J. Corey,Michael J. Hession,Rameez Ishaq,Arinola Awomolo,Shirin Hasan,Chirag Shah,Hui Liu,Amittha Wickrema,Najet Debili,John D. Crispino,Elizabeth A. Eklund,Yolande Chen

View Articletitled, Dynamins 2 and 3 control the migration of human megakaryocytes by regulating CXCR4 surface expression and ITGB1 activity

Supplemental data

TRANSFUSION MEDICINE

Robust adaptive immune response against Babesia microti infection marked by low parasitemia in a murine model of sickle cell disease

Woelsung Yi,Weili Bao,Marilis Rodriguez,Yunfeng Liu,Manpreet Singh,Vijendra Ramlall,Jeny R. Cursino-Santos,Hui Zhong,Catherine M. Elton,Gavin J. Wright,Avital Mendelson,Xiuli An,Cheryl A. Lobo,Karina Yazdanbakhsh

View Articletitled, Robust adaptive immune response against Babesia microti infection marked by low parasitemia in a murine model of sickle cell disease

Supplemental data

ERRATUM

Bye AP, Unsworth AJ, Desborough MJ, et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv. 2017;1(26):2610-2623.

View Articletitled, Bye AP, Unsworth AJ, Desborough MJ, et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv. 2017;1(26):2610-2623.

Cover Image

Cover Image

COVER FIGURE
Representative immunofluorescence image of a splenic section from a Babesia microti–infected mouse. Germinal centers marked by peanut agglutinin (green) are formed similarly in HbAA-Townes control mice and transgenic HbSS-Townes mice after infection. See the article by Yi et al.
Front Matter
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read
Most Cited

Imus PH, Pasca S, Tsai H-L, et al. Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies. Blood Adv. 2024;8(14):3849-3858.

A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis

In vivo silencing of intestinal DMT1 mitigates iron loading in β-thalassemia intermedia (Hbb^th3/+) mice

Antithrombotic efficacy and bleeding risks of vaccine-induced immune thrombotic thrombocytopenia treatments

Advertisement intended for health care professionals

Table of Contents

EXCEPTIONAL CASE REPORTS

Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion
Clinical Trials & Observations

Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma
Clinical Trials & Observations

HEMATOPOIESIS AND STEM CELLS

GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cells

IMMUNOBIOLOGY AND IMMUNOTHERAPY

CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling

LYMPHOID NEOPLASIA

Ablation of miR-146b in mice causes hematopoietic malignancy

p53 regulates CD46 expression and measles virus infection in myeloma cells

The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma

MYELOID NEOPLASIA

The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy

Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis

PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation
Clinical Trials & Observations

PLATELETS AND THROMBOPOIESIS

Nfe2 is dispensable for early but required for adult thrombocyte formation and function in zebrafish

Dynamins 2 and 3 control the migration of human megakaryocytes by regulating CXCR4 surface expression and ITGB1 activity

TRANSFUSION MEDICINE

Robust adaptive immune response against Babesia microti infection marked by low parasitemia in a murine model of sickle cell disease

ERRATUM

Bye AP, Unsworth AJ, Desborough MJ, et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv. 2017;1(26):2610-2623.

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

EXCEPTIONAL CASE REPORTS

Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion Clinical Trials & Observations

Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma Clinical Trials & Observations

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation Clinical Trials & Observations

PLATELETS AND THROMBOPOIESIS

TRANSFUSION MEDICINE

ERRATUM

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion
Clinical Trials & Observations

Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma
Clinical Trials & Observations

PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation
Clinical Trials & Observations